Twigman - PBT HD trial had primary endpoints of safety and...

Twigman - PBT HD trial had primary endpoints of safety and tolerability, whereas IVX lupus trial has safety, tolerability and reduction in IL6 as primary endpoints. The lupus trial announcement states that Lupus is a vascular inflammation disease, and that IL6 is a marker of vascular inflammation. From a quick google search I can find multiple studies supporting IL6 as being correlated to symptoms of Lupus disease. therefore I have no reason to believe why it wouldn't be an accurate measure of the drugs actual impact on the disease. It certainly offers more than just tolerability as a primary endpoint. PBT HD secondary endpoint actually focused on the efficacy in terms of motor, functional and behavioural symptoms, which it failed according to the article u provided. Therefore PBT got away with the trial being deemed a success based on the primary endpoint, even though the drug showed no positive impact on core efficacy measures, whereas IVX lupus trial will not have this possibility since efficacy (IL6) is a primary endpoint.

It's amazing how PBT MC is multiples of ours and they just have one phase 2 that barely passed, and one that failed. IVX is hugely undervalued IMO, but we all know that ;)